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ABSTRACT
After the landmark approval of T-VEC, oncolytic viruses are finding their way to the 
clinics. However, response rates have still room for improvement, and unfortunately there 
are currently no available markers to predict responses for oncolytic immunotherapy. 
Interleukin 8 (IL-8) production is upregulated in many cancers and it also connects 
to several pathways that have been shown to impair the efficacy of adenoviral 
immunotherapy. We studied the role of IL-8 in 103 cancer patients treated with oncolytic 
adenoviruses. We found high baseline serum IL-8 concentration to be independently 
associated with poor prognosis (p<0.001). Further, normal baseline IL-8 was associated 
with improved prognostic potential of calculation of the neutrophil-to-lymphocyte 
ratio (p<0.001). Interestingly, a decrease in IL-8 concentration after treatment with 
oncolytic adenovirus predicted better overall survival (p<0.001) and higher response 
rate, although this difference was not significant (p=0.066). We studied the combination 
of adenovirus and IL-8 neutralizing antibody ex vivo in single cell suspensions and 
in co-cultures of tumor-associated CD15+ neutrophils and CD3+ tumor-infiltrating 
lymphocytes derived from fresh patient tumor samples. These results indicate a role 
for IL-8 as a biomarker in oncolytic virotherapy, but additionally provide a rationale for 
targeting IL-8 to improve treatment efficacy. In conclusion, curtailing the activity of IL-8 
systemically or locally in the tumor microenvironment could improve anti-tumor immune 
responses resulting in enhanced efficacy of adenoviral immunotherapy of cancer.
INTRODUCTION
After years of development, the first oncolytic viruses 
are currently entering the clinics as cancer therapeutics with 
products approved in both the East and West [1–3]. Despite 
recent discoveries relating to the mechanisms of action 
and factors that influence the efficacy of oncolytic viruses 
[4–6], there is still a critical need to identify pathways that 
determine the response to virotherapy and survival benefits 
thereafter. In this regard, analysis of patient data is of key 
importance since immunological effects of human-specific 
agents may significantly differ between humans and 
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experimental animals. In clinical trials, oncolytic viruses 
have demonstrated a favorable safety profile and promising 
anti-tumor efficacy [7]. However, there is still room for 
improvement with regard to the frequency of anti-tumor 
responses, especially in patients with significant metastasis 
burden. Identification and characterization of pathways 
associated with the activity of oncolytic viruses could reveal 
potential targets for improving the efficacy of virotherapy. 
Moreover, understanding the key molecular mechanisms 
would help selection of the right patients for therapy.
Interleukin 8 (IL-8) was originally discovered 
as a neutrophil chemoattractant isolated from human 
monocytes in the 1990’s [8]. Since then, activated 
IL-8 signaling has been identified in different cancers 
with one of its many effects relating to regulation of 
angiogenesis [9]. In tumors, IL-8 has also been proposed 
to have a role in promotion of survival, cell proliferation, 
chemoresistance and metastasis formation [10, 11]. There 
have been several attempts to therapeutically target the 
IL-8 pathway in the context of cancer and other diseases, 
and some approaches have demonstrated promising 
efficacy [12–15]. However, to date no therapies targeting 
IL-8 have been approved for clinical use.
A number of different viruses have been shown 
to promote IL-8 production and it is a key mediator 
of neutrophil dependent pathogenesis in many viral 
infections [16–18]. Some adenovirus serotypes, notably 
serotypes 7 and 19 [19, 20], also upregulate IL-8 and 
recruit neutrophils to the infection site. Interestingly, 
considering the use of viruses in cancer immunotherapy, 
systemic neutrophil expansion has been linked to 
metastasis formation in murine tumor models [21]. In 
contrast to the wild-type viruses, at least one oncolytic 
adenovirus has also been recently shown to decrease IL-8 
signaling in preclinical tumor models [22].
To our knowledge, there are no previous human data 
on the effects of IL-8 in the context of oncolytic viruses, 
excluding limited data from the phase II trial of oncolytic 
reovirus [23]. We have previously demonstrated that high 
levels of pre-existing activity of innate immune system 
results in lower survival of patients receiving oncolytic 
adenovirus [24], and – conversely - that patients with low 
baseline immune activation are more likely to benefit 
from oncolytic immunotherapy. This probably relates 
to the unparalleled ability of oncolytic viruses to turn 
immunologically cold tumors into hot inflamed tumors [2], 
which may underlie an important part of their mechanism 
of action. In tumors already inflamed, this aspect of the 
therapy probably adds little (although oncolytic cell lysis 
could still result in anti-tumor effects). Additionally, low 
pre-treatment levels of HMGB1, which is associated 
with immunogenic cell death but also mediates chronic 
inflammation under a steady state, have been linked to 
better survival and therapeutic efficacy [25, 26]. This 
background provides a strong rationale for investigation of 
the role of IL-8 in immunotherapy with oncolytic viruses.
The aim of this study was to examine how IL-8 
activity shapes the responses to treatment with oncolytic 
adenovirus. We analyzed baseline serum IL-8 in 103 
patients treated with oncolytic adenovirus and measured 
post-treatment changes in IL-8. We then compared 
these findings to available survival and response data. 
In additional analyses, we compared serum IL-8 levels 
to tumor type and tumor load. We also assessed how 
different treatment characteristics affect IL-8 changes. 
Due to the close connection between IL-8 and neutrophils, 
their associations were investigated in peripheral blood. 
To evaluate the role of tumor-derived IL-8 on survival, 
expression levels of IL-8 and its receptors CXCR1 and 
CXCR2 were quantified by RNA microarrays from pre- 
and post-treatment tumor samples from oncolytic virus 
treated patients. Finally, we analyzed the anti-tumor and 
immunostimulatory activity of a combination of IL-8 
blockade and oncolytic adenovirus in human ovarian 
tumor samples obtained fresh from the operating room.
RESULTS
Normal baseline IL-8 before treatment with 
oncolytic adenovirus correlates with longer 
overall survival
Baseline IL-8 levels were measured from pre-
treatment peripheral blood samples of 103 patients 
(Supplementary Table 1). Patients were divided into 
high and low baseline groups based on the “normal” 
laboratory reference range for serum IL-8 (“normal” is 
below 62 ng/l). Survival between high and low baseline 
groups was compared using the Kaplan-Meier method. 
We found significant differences in the survival of high 
and low baseline IL-8 patients (p<0.001) (Figure 1A). We 
also measured other inflammatory cytokines, including 
IL-6, IL-10, TNFα and GM-CSF, in baseline serum 
samples, but found no differences in overall survival when 
using reference values or even sample median as cutoff 
(Supplementary Figure 1A-1D). Despite a clear difference 
in survival, there was only a non-significant trend between 
baseline IL-8 and treatment response, although the number 
of patients imaged and the nowadays well appreciated 
phenomenon of pseudoprogression [27] could have 
impacted the p-value. The proportions of patients displaying 
disease control were 53% and 33% in IL-8 low and high 
groups, respectively (p=0.182) (Figure 1B).
IL-8 levels in patients with different tumor types, 
tumor load and pre-treatment leucocyte counts
Different tumor types had slightly diverging average 
serum IL-8 levels (Figure 1C), but the differences were 
not considered statistically significant. When patients were 
grouped based on the calculated tumor load score, which 
reflected the overall tumor burden of the patient, average 
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serum IL-8 concentrations seemed to be slightly higher, 
although not significantly, in patients with high tumor load 
score (Figure 1D). This difference was mainly due to three 
outlier patients with exceptionally high IL-8 levels.
Since IL-8 is known to function as a chemoattractant 
for immune cells, and especially neutrophils, we analyzed 
the pre-treatment cell counts of two major leucocyte 
subsets, neutrophils and lymphocytes, in 86 patients for 
whom also IL-8 data was available. We then grouped the 
patients into high and low lymphocyte and neutrophil 
count groups, and compared baseline IL-8 levels between 
these groups (Figure 1E). Difference in IL-8 levels was 
larger between the low and high neutrophil groups in 
comparison to the difference between low and high 
lymphocyte groups, although the neutrophil groups did 
not differ significantly (p=0.085).
Post-treatment decrease in IL-8 independently 
predicts improved overall survival
We measured changes in IL-8 levels, following 
each patient’s first treatment with oncolytic adenovirus. 
Patients were categorized into increase, decrease and 
no-change groups based on post-treatment IL-8 levels 
(Supplementary Figure 2). The minimal requirements 
for increase and decrease were a 100% growth and a 
50% decline from baseline IL-8 levels during adenoviral 
immunotherapy, respectively. We analyzed survival 
between these three groups and found patients with post-
treatment IL-8 decrease to have significantly longer 
overall survival (p<0.001) (Figure 2A).
Imaging responses after treatment were also 
compared between IL-8 change groups (Figure 2B). 
Figure 1: Overall survival and treatment responses in patients with normal and high pre-treatment IL-8 levels in blood 
and IL-8 concentrations in different tumor groups. Patients were grouped based on the laboratory reference value for normal IL-8 
(<62 ng/l). Asterisks indicate statistical significance: *** p<0.001, ** p<0.01 and * p<0.05. (Panel A) Overall survival was significantly 
longer in patients with normal IL-8 before treatment (n=53, median OS 147 days) when compared with high IL-8 patients (n=50, median 
OS 93 days, p<0.001). (Panel B) Imaging response information was available for 59 patients, with baseline IL-8 measurements (normal 
IL-8 n=38, high IL-8 n=21). No significant difference in disease control rate was observed between the IL-8 groups (Fisher’s exact test 
p=0.182). (Panel C) Mean pre-treatment IL-8 concentrations in patients with different tumor types. The differences were not considered 
significant. Error bars are shown as mean + SEM in all panels. (Panel D) Scatter plot presenting IL-8 levels in patients with high and low 
tumor load scores. Vertical line indicates sample mean. The difference was not significant (p=0.187). (Panel E) Mean IL-8 concentrations in 
patients with high and low lymphocyte/neutrophil counts. Patients were grouped based on median lymphocyte/neutrophil count. Difference 
between high and low neutrophil count patients was not significant (p=0.085).
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Interestingly, this comparison revealed an almost two-fold 
difference in disease control rate between IL-8 decrease 
and the other two groups. However, partly due to the 
small sample size, the difference did not reach statistical 
significance despite pooling of the increase and no-
change groups (Fisher’s exact test p=0.066). In additional 
analyses, when both baseline IL-8 status and IL-8 change 
were taken into account, decrease in IL-8 seemed to 
correlate with a higher disease control rate. The effect was 
similar in both high and low baseline groups (Figure 2C), 
but the differences were not considered significant.
To further validate the survival effect of both 
baseline IL-8 and IL-8 change, we constructed a 
multivariate proportional hazards model with clinical 
variables of the patients (Supplementary Table 2). In this 
analysis, normal baseline IL-8 and post-treatment IL-8 
decrease were associated with significantly lower hazard 
ratios for tumor related mortality (HR 0.502, p=0.010 
and HR 0.270, p=0.001, respectively), which supports 
their role as independent prognostic factors for adenoviral 
immunotherapy. Impressively, IL-8 decrease was the 
strongest prognostic factor in this analysis, even stronger 
than the general condition (WHO classification) or tumor 
type of the patients.
Treatment characteristics do not explain the 
observed changes in IL-8 levels
To investigate whether the characteristics of the 
treatment influence the post-treatment IL-8 change, we 
correlated IL-8 changes with treatment virus type (capsid), 
the arming device (transgene) or concomitant “virus 
Figure 2: Effect of IL-8 change status on overall survival and treatment responses. Asterisks indicate statistical significance: 
*** p<0.001, ** p<0.01 and * p<0.05. (Panel A) Overall survival in different IL-8 change groups. Median survivals were 167, 71 and 120 
days for decrease, increase and no change groups, respectively (p<0.001). (Panel B) Disease control rates for patients with IL-8 decrease 
(n=9), increase (n=31) and no change (n=16). Fisher’s exact test p=0.066 (after pooling no change and increase groups). (Panel C) Separate 
disease control rates in IL-8 change groups for patients with normal or high baseline IL-8 (normal IL-8: decrease n=4, no change n=8, 
increase n=23. high IL-8: decrease n=5, no change n=8, increase n=8). The differences in disease control rates were not considered 
significant (Fisher’s exact test p=0.177).
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sensitizing” treatment (Supplementary Figure 3). In these 
comparisons, we observed no significant differences between 
patients who received virus coding for no transgenes or 
coding the immunostimulatory granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Supplementary 
Figure 3A) or virus with Ad5 capsid [28] or chimeric Ad5/3 
capsid [29] (Supplementary Figure 3B). Additionally, 
IL-8 changes were not impacted by concomitant low-dose 
cyclophosphamide which was used to reduce regulatory 
T-cells [30] (Supplementary Figure 3C).
IL-8 and IL-8 receptor RNA expression in tumor 
samples
To quantify IL-8 at the tumor site, we measured 
RNA expression from pre- and post-treatment tumor or 
ascites/pleural fluid samples from an additional cohort 
of 15 patients treated with oncolytic adenoviruses 
(Supplementary Table 3). Together with IL-8, we analyzed 
expression of the two IL-8 receptors CXCR1 and CXCR2 
(Figure 3A). Variation in pre-treatment expression levels 
and pre-post changes was remarkably larger for IL-8 
compared to its receptors, and thus we focused on IL-8 in 
subsequent analyses.
For survival analysis, patients were grouped based 
on the baseline tumor-level expression of IL-8 mRNA 
and pre-post treatment change in expression (Figure 3B–
3C). Change in IL-8 expression was not correlated with 
overall survival, but as seen for IL-8 analysis in blood, 
we observed an interesting trend for longer survival 
in patients with low pre-treatment IL-8 expression in 
tumors, although the difference did not reach statistical 
significance (p=0.058) in this small patient cohort.
Baseline IL-8 status improves the prognostic 
value of anti-tumor T cell ELISPOT activity and 
neutrophil-to-lymphocyte ratio
We evaluated the effects of baseline IL-8 in 
the context of anti-tumor T cell activity, as measured 
Figure 3: Tumor IL-8 and IL-8 receptor mRNA expression. (Panel A) mRNA expression for IL-8 and its receptors CXC 
chemokine receptor 1 (CXCR1) and 2 (CXCR2) was quantified from pre- and post-treatment tumor samples. Expression is presented as 
log2-transformed values. (Panel B) Overall survival in different IL-8 expression groups. Patients were grouped based on the pre-treatment 
IL-8 expression level. Median OS was 174 days in the low expression group and 72 days in the high expression group (n=15, p=0.058). 
(Panel C) IL-8 expression change was determined as the difference between pre- and post-treatment expression values. No significant 
difference in survival between decrease and increase groups was found.
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by anti-survivin ELISPOT performed on peripheral 
blood mononuclear cells, and pre-treatment neutrophil-
to-lymphocyte ratio. In this analysis, we studied the 
correlation of anti-tumor T cell activity with overall 
survival separately for normal and high IL-8 patient 
groups (Figure 4A–4B). For patients with high baseline 
IL-8, T cell activity did not seem to associate with frequent 
long-term survival, whereas in patients with normal IL-8 T 
cell activity, effects on survival seemed more prominent. 
The difference was, however, not significant in this small 
patient group (n=23, p=0.052).
We have previously found that neutrophil-to-
lymphocyte ratio (NLR) significantly predicts survival 
in patients treated with oncolytic adenovirus [6]. In order 
to verify that IL-8 is not merely reflecting the neutrophil/
lymphocyte balance in these patients, we combined 
baseline IL-8 and neutrophil-to-lymphocyte ratio status 
in a survival analysis (Figure 4C). Here we found a 
significant improvement in the prognostic value of both 
factors when used in a combination approach (p<0.001).
IL-8 blockade can augment the anti-tumor 
activity of oncolytic adenovirus in human 
ovarian tumor cell suspensions
Having established that baseline IL-8 and IL-8 
change during treatment are important with regard to 
survival of patients treated with oncolytic adenoviruses, 
we next wanted to study whether this was a passive 
phenomenon or if there was some causal relationship. 
Animal studies were not possible since mice lack IL-8 
[31]. Thus, we obtained ovarian tumor specimens fresh 
from the operating room. Importantly, these samples 
contained not only the tumor cells, but also cells of the 
tumor microenvironment, including tumor-infiltrating 
lymphocytes and neutrophils.
Figure 4: Overall survival in patients with different baseline T cell activity status, neutrophil-to-lymphocyte ratio 
(NLR) and IL-8 levels. Patients with increase or decrease in post-treatment anti-survivin were included in the T cell activity group, 
while patients with no change in the ELISPOT were assigned to anergy group. Asterisks indicate statistical significance: *** p<0.001, ** 
p<0.01 and * p<0.05. (Panel A) Median overall survivals in high baseline IL-8 patients were 104 and 114 days in anti-survivin T cell anergy 
and activity groups, respectively. The difference was not considered significant. (Panel B) for patients with normal baseline IL-8, median 
overall survivals were 104 and 114 days in anti-survivin T cell anergy and activity groups, respectively (p=0.052). (Panel C) Pre-treatment 
NLR and IL-8 values were used to stratify patients into different groups. Overall survival was significantly increased in patients with low 
IL-8 and low NLR (p<0.001).
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To study the feasibility of the combination of 
oncolytic adenovirus and IL-8 blocking antibody, we 
tested the cell killing abilities of the combination in an 
MTS cell viability assay using single cell suspensions from 
human ovarian tumors samples (Figure 5). In these pilot 
experiments, anti-IL-8 antibody increased tumor cell killing 
in some – but not all – conditions, which likely reflects 
heterogeneity between different tumors. Future studies 
with larger sample sizes could provide more accuracy on 
the magnitude of the effect. In these studies it is vital to 
characterize the tumors not only based on histological type, 
but also on the immunological and genetic bases, in order to 
gain more knowledge about the genetic and immunological 
factors that determine responses to this treatment. Of note, 
the effect of IL-8 blocking would be expected to be most 
prominent in vivo where the immunological effects of IL-8 
play a role. Therefore, it was important to establish that anti-
IL-8 antibody did not blunt the oncolytic functionality of 
Ad5/3-d24, which is an unarmed oncolytic adenovirus [32].
IL-8 blockade together with adenovirus can 
influence TIL proliferation and activation when 
co-cultured with TANs isolated from ovarian 
tumors
Human ovarian tumor samples were processed 
to extract tumor infiltrating lymphocytes (TIL) and 
tumor associated neutrophils (TAN) for analyses of the 
Figure 5: Tumor cell viability in human ovarian tumor cell suspensions following treatment with oncolytic adenovirus, 
recombinant IL-8 or anti-IL-8 antibody. Cell viability was measured using a MTS assay on days 7-13 after the start of incubation. 
Viability is presented as percentage of mock group cell viability. Ad = Ad5/3-d24. aIL8=anti-IL-8=anti-IL-8 neutralizing antibody. 
rIL8=IL-8 = recombinant IL-8. Asterisks indicate the significance of findings: * (p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001). (Panel 
A) Results from Tumor 1. (Panels B-C) Results from Tumor 2. (Panel D) Results from Tumor 4. (Panels E-F) Results from Tumor 5. 
(Panels G-H) Results from Tumor 6. (Panel I) Results from Tumor 7.
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immune effects of adenovirus and anti-IL-8 antibody 
combination. Of note, co-incubation of TILs with TANs 
did not notably suppress T cell proliferation, possible due 
to the strong exogenous stimuli by anti-CD3/anti-CD28 
beads (Supplementary Figure 4). After a 6-day incubation, 
monotherapy with IL-8 blocking antibody was unable to 
increase T cell proliferation and in some cases even seemed 
to reduce the number of TILs. In contrast, addition of 
adenovirus into the anti-IL-8 therapy regimen was able 
to restore the T cell levels to same as in the mock group. 
A similar pattern was observed in cytotoxic T cell (CTL) 
activation (Figure 6A–6B, Supplementary Figure 5), but 
not in helper T cell activation (Supplementary Figure 6). 
However, it needs to be noted that the exact biological 
consequences of changes of this magnitude have not been 
clearly established, and additional functional studies would 
be needed to define the actual immunostimulatory impact.
In addition to TIL proliferation and activity, 
endogenous secretion of IL-8 was measured from TIL 
and/or TAN cultures after 24 h incubation ex vivo (Figure 
6C–6D). Interestingly, TANs produced higher levels of 
IL-8 compared to TILs, possibly reflecting the actual 
situation in human tumors in vivo [33]. In addition, the 
functionality of anti-IL-8 antibody was confirmed as it was 
able to efficiently bind IL-8 from the suspension, leading 
to decrease in detected IL-8. Importantly, addition of 
adenovirus into the TIL:TAN co-culture did not elevate the 
levels of IL-8 (Figure 6C). Instead, presence of adenovirus 
resulted in a reduced IL-8 concentration when compared 
to mock treated co-cultures or TANs alone (Figure 6D). 
This suggests that oncolytic Ad5/3-d24 adenovirus is not 
likely to cause counterproductive IL-8 induction when 
used together with IL-8-blocking antibodies.
DISCUSSION
In this study we initially evaluated the predictive and 
prognostic role of interleukin 8 in the context of adenoviral 
immunotherapy. We found both normal pre-treatment IL-8 
and pre-post decrease to be independently associated with 
Figure 6: Cytotoxic T cell activation and IL-8 production in ovarian tumor derived TIL and TAN co-cultures obtained 
from human patients. (Panels A-B) Cytotoxic T cell activation was measured after a 6 day incubation of TIL-TAN co-cultures or TILs 
alone. Bars represent the percentage of activated CD25/CD69-positive cytotoxic T cells in the culture. Ad = Ad5/3-d24. Representative 
examples from Tumors 1 and 7, complete data in Supplementary Figure 5. Activation marker CD25 was used for samples from Tumor 1 
and activation marker CD69 for samples from Tumor 7. (Panels C-D) IL-8 concentration was measured after a 24 hour incubation from 
TIL-TAN co-cultures or TILs/TANs alone. Ad = Ad5/3-d24. rIL8 = recombinant IL-8. Asterisks indicate the significance of findings: * 
(p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001).
Oncotarget6328www.impactjournals.com/oncotarget
significantly improved overall survival. There was also 
preliminary evidence of higher disease control rate in patients 
with IL-8 decrease, although statistical significance was not 
reached, which was probably influenced by patient number 
and, more importantly, the phenomenon of inflammatory 
pseudo-progression which has resulted in many false 
negatives in cancer immunotherapy [27, 34]. While this 
phenomenon is currently well established, it was not fully 
appreciated when these treatments were given, resulting in 
premature abrogation of therapy and incorrect conclusions 
of lack of efficacy.
In an extension cohort of patients, low baseline IL-8 
RNA expression in tumor biopsy or effusion samples showed 
a trend for longer overall survival. In contrast to intracellular 
and paracrine factors [26, 35], local analysis of IL-8 
expression did not seem to be more sensitive (for prognostic 
value) over serum analysis of the soluble IL-8 protein, which 
is logical given the secretory nature and systemic activity of 
this key cytokine. Combining pre-treatment IL-8 status with 
anti-tumor T cell activity data or neutrophil-to-lymphocyte 
ratio improved the prognostic potential of both variables. 
In ex vivo studies with ovarian tumor samples we found 
preliminary evidence that in some instances IL-8 blockade 
could potentiate oncolytic adenovirus–mediated killing 
of tumor cells. Moreover, adenovirus seemed to be able to 
counteract the reduction in the number of TILs following 
treatment with anti-IL-8 antibodies.
The prognostic value of blood IL-8 has been 
previously documented in several cancers [11, 36, 
37]. IL-8 has various pro-tumor effects in the tumor 
microenvironment [10], which explains its effects on overall 
survival. However, as reported here, the prognostic and, to 
some extent, predictive value of post-treatment IL-8 change 
suggests a specific role for IL-8 in the context of adenovirus 
based immunotherapy. Moreover, the effects of baseline 
IL-8 and post-treatment change seemed to be independent 
of each other, both providing a non-synonymous and 
perhaps synergistic approach for identifying patients likely 
to benefit from oncolytic immunotherapy (Figure 2C). This 
is highlighted by the fact that all patients with low baseline 
and subsequent decrease in IL-8 (n=4) responded to the 
treatment (disease control or better). However, although 
our data suggest that neutrophils may play a role, the 
full mechanistic basis of the effect of IL-8 on efficacy of 
adenoviral therapy is unclear and needs to be clarified in 
the future. In addition, the improved survival of patients 
with IL-8 increase compared to the no-change group, which 
could indicate beneficial immunological responses [38] or 
immunogenic cell death [25] of tumor cells in a subset of 
these patients who are actually responding to the treatment, 
calls for further studies. These studies, however, will be 
challenging to perform in the laboratory, since mice lack 
IL-8 [31].
Since study was not based on a clinical trial, it 
included patients with multiple different cancer types. 
While this heterogeneity can be seen as a weakness, it can 
also be considered a strength since the patient population 
resembles a “real life” population of cancer patients seen 
by a solid tumor oncologist. Furthermore, previous work 
has shown that IL-8 is relevant in numerous cancer types, 
which gives additional rationale to the approach. As there 
were no significant differences in the pre-treatment IL-8 
levels between different tumor types, the results may 
illustrate a phenomenon present across several cancer 
types. Alternatively, tumor specific variation in IL-8 
activity could eclipse tumor type specific variation, 
which would call for an entirely personalized approach 
when selecting the treatments. Nevertheless, it needs to 
be emphasized that the findings have to be verified in 
additional studies focusing on specific tumor types which 
also include analysis on the immunological type of the 
tumors. Different treatment characteristics did not alter 
the distribution of IL-8 changes. This suggests that neither 
adenovirus design nor the concomitant treatments used 
affected the IL-8 pathway. Some chemotherapies, such as 
oxaliplatin and taxanes, have been proposed to increase 
IL-8 signaling [39–41]. This is potentially important when 
considering combination treatments with oncolytic viruses 
in future trials, as they might interfere with immunological 
effects of the virus via IL-8.
Low local expression of IL-8 mRNA showed an 
intriguing trend for increased survival, although the 
finding was not statistically significant in this limited 
patient sample (p=0.058). However, this finding was in 
accord with the survival associations of systemic levels of 
IL-8. Thus, it seems conceivable that the IL-8 present in 
blood of cancer patients is at least partly tumor-derived, 
although the exact cell types producing the cytokine could 
not be identified with the microarray assay. We saw no 
correlation between survival and change of IL-8 RNA 
expression, which could indicate that other cell types, such 
as T cells and neutrophils, also affect the kinetics of serum 
IL-8. While our data suggests that baseline IL-8 protein 
levels may be determined by IL-8 mRNA expression by 
the tumor and its microenvironment, change in systemic 
IL-8 levels could be more influenced by treatment effect 
on the immune cells secreting IL-8 [42]. For example, 
well known sequelae of oncolytic adenovirus replication, 
such as pathogen associated molecular pattern recognition 
danger signaling [43] and immunogenic cell death [25] 
could shift neutrophil differentiation towards anti-tumor 
N1 neutrophils, as discussed below, to attenuate IL-8 
production following therapy. On the other hand, increase 
in IL-8 levels could indicate IL-8 release from other cell 
types, such as macrophages, as a response to effective 
immunostimulation by the adenovirus, which is why it 
will be key to better dissect these counteracting forces 
going forward. It is also possible that mRNA levels may 
not be directly predictive of IL-8 cytokine production, 
since IL-8 synthesis is regulated also after transcription 
[42]. Nevertheless, additional studies are needed to clarify 
the inherent causalities as well as the primary source and 
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kinetics of IL-8, both at the systemic level and in the 
tumor micro-environment.
High neutrophil counts were associated with 
elevated pre-treatment IL-8 concentrations, although the 
difference was not significant due to high variation. The 
association of high IL-8 and high neutrophils is logical, 
since neutrophil recruitment and activation is one of the 
main functions of IL-8 [44]. We have previously found 
that neutrophil-to-lymphocyte ratio predicts survival 
in adenovirus treated cancer patients [6]. Therefore, it 
was interesting that IL-8 status was able to improve its 
predictive ability significantly. One possible hypothesis 
explaining this effect is that IL-8 reflects (or even 
influences) neutrophil subtype along the pro-tumor/anti-
tumor axis, although such a role has been previously 
assigned primarily to TGF-β and IFN-β [45, 46]. Again, 
IL-8 may have been discriminated against, since it cannot 
be studied in mice. Pro-tumor neutrophils have been 
shown to attenuate T cell responses [21, 45], in contrast 
to normal neutrophils that promote T cell activity [47], 
lending support to the notion that factors such as IL-
8, which are able to influence neutrophil behavior, 
could have central roles in immuno-oncology and its 
modulation. Moreover, the ELISPOT data reported here 
suggests that IL-8 could influence T cell activity, possibly 
via immunosuppressive tumor-associated neutrophils.
Baseline blood HMGB1 (High mobility group box 1) 
has previously been shown to be an independent predictive 
and prognostic factor in patients treated with oncolytic 
adenovirus [26]. Thus it is intriguing that HMGB1 has 
been linked to the IL-8 pathway in an immunologically 
relevant manner [48] in the context of cancer [49]. A recent 
study indicated benefits for combining both HMGB1 and 
IL-8 inhibition in experimental gastric cancer models 
[50]. Based on our data, similar combinations could 
yield increased anti-tumor effects also in the context of 
adenoviral immunotherapy.
In addition to HMGB1, we have found that the 
expression of its receptor TIM-3 in pre-treatment tumor 
samples is associated with worse prognosis in adenovirus 
treated patients [24]. Previous studies on the function of 
TIM-3 in the context of cystic fibrosis have demonstrated 
first that TIM-3 activation induces IL-8 production [51], but 
also that IL-8 promotes expression of TIM-3 [52]. Thus, 
although the exact interdependencies of IL-8 and TIM-
3 are unclear, they may relate to phenomena important 
for the efficacy of oncolytic adenovirus specifically 
and anti-tumor immunotherapy more generally. These 
links are also interesting considering the development of 
immunotherapies targeting TIM-3 [53, 54].
One important use of IL-8 quantitation, with or 
without concomitant neutrophil-to-lymphocyte ratio 
measurement, could relate to its value as a biomarker. 
Baseline measurement (Figure 1) would be fast, 
inexpensive and the test is routinely available. Moreover, 
given its rapid dynamics (Supplementary Figure 2), the 
measurement could be repeated a week after treatment 
initiation to identify benefiting patients. Given the high 
cost of new cancer drugs, in particular when used in 
combination, biomarkers could be useful in justifying their 
use, and in increasing the proportion of patients benefiting 
from the investment. In a patient with high baseline IL-8 
and lack of IL-8 decrease, perhaps switching to another 
therapy is more appropriate that continuing with oncolytic 
immunotherapy. In our patient series, there was only a 
25% chance of disease control in such patients. These sort 
of hypotheses should be justified in prospective trials, of 
course.
Perhaps the more important or interesting question 
is whether IL-8 can be manipulated to enhance the anti-
tumor potential of adenovirus treatments. Past efforts to 
target IL-8 in cancer treatment have displayed promising 
results in preclinical models [12, 13], but clinical trials 
with these agents have not been completed. One approach 
utilized replication-incompetent oncolytic adenoviruses 
expressing short hairpin RNAs against IL-8 [55]. This 
treatment was shown to inhibit tumor progression and 
metastases in xenograft models. In addition to cancer, IL-8 
blocking antibodies have been studied in the context of 
other diseases. Although efficacy trials have not yet been 
completed, the available early data suggests a favorable 
safety profile in the context of COPD and palmoplantar 
pustulosis [14, 15], which might predict tolerability also 
in cancer trials.
One caveat of previous IL-8 targeting treatments 
has been focus on just tumor growth inhibition and 
anti-angiogenesis, instead of taking into account 
immunological aspects. Thus, new studies of IL-8 
blockade in the context of immunotherapy, and especially 
with oncolytic adenoviruses, are needed, but - as 
mentioned – these studied are complicated due to the fact 
that mice do not have IL-8. Xenograft studies thus only 
take into account human IL-8 produced by the tumor cells. 
Neutrophils, which were implicated in our analyses with 
human substrates, would probably not react to human 
IL-8 in xenograft studies as they would originate from 
the mouse. Therefore, future studies should be focused 
on human-derived tumor samples, although these can 
be sometimes difficult to obtain in large numbers, and 
especially TANs in order to accurately dissect these 
immunological phenomena. In the current flux of emerging 
immunotherapeutic approaches, IL-8-targeting represents 
an interesting example, as it has been considered as a 
potential treatment quite recently, but unfortunately 
discarded without assessing its immunological properties.
To evaluate the feasibility of combination 
treatment, we investigated the oncolytic and 
immunostimulatory effects of IL-8 blockade together 
with oncolytic adenovirus in human ovarian tumor 
samples ex vivo. As expected, anti-IL-8 treatment 
alone was not able to increase cell killing in this 
setting, due to lack of direct effects on tumor cells. 
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Nevertheless, IL-8 blockade did not have harmful 
impacts on the oncolytic activity of adenovirus 
either, which is important considering a combination 
approach. In some cases, the combination was even 
able to increase tumor cell killing. Importantly, 
combining adenovirus to anti-IL-8 seemed to improve 
T cell proliferation and CTL activation, which were 
reduced when only anti-IL-8 antibody was present, 
although it needs to be noted that the exact biological 
significance of the change of this magnitude is not 
known. Of note, despite what has been proposed 
for some wild type viruses [17–20], we found that 
infection with oncolytic adenovirus did not increase 
IL-8 secretion. Instead, reduction of IL-8 was seen in 
comparison to untreated TIL-TAN co-cultures.
In summary, we have demonstrated an independent 
correlation between overall survival and both baseline 
IL-8 and post treatment IL-8 change in patients treated 
with adenoviral immunotherapy. Both low baseline IL-8 
and IL-8 decrease were associated with superior clinical 
outcomes. Taking into account both variables seemed to 
increase the sensitivity of detection of patients likely to 
benefit. In contrast, prognosis was poor in patients with 
high IL-8 expression in their tumor or in the systemic 
circulation. Activity of IL-8 is likely to be at least 
partly mediated by the circulating and tumor-associated 
neutrophils. Initial studies on combination treatment 
with oncolytic adenovirus and IL-8 blockade in human 
ovarian tumor samples validated the feasibility of the 
combination, and provide rationale for further studies. 
Based on our results, IL-8 is a promising candidate 
biomarker for adenoviral immunotherapy and interesting 
target for improving the efficacy of oncolytic adenovirus. 
The obvious next step is to construct an oncolytic 
adenovirus coding for an anti-IL-8 molecule and then 
devise a way to test it preclinically, prior to possible 
clinical application.
MATERIALS AND METHODS
Patients treated with oncolytic adenoviruses
All patients who were treated with oncolytic 
adenoviruses participated in the Advanced Therapy 
Access Program (ATAP), which was a personalized 
therapy program [56]. Patients who were treated in ATAP 
had solid tumors refractory to standard treatments and no 
major organ dysfunctions. A more detailed description 
of the exclusion criteria has been previously reported 
[57]. Written informed consent was received from all 
of the patients before participation in the treatment 
program, and the studies performed on patient materials 
were positively evaluated by the Helsinki University 
Central Hospital Operative Ethics Committee (HUS 
62/13/03/02/2013).
Oncolytic viruses
Viruses that were used in the treatments have been 
previously published [28, 29, 58–62]. All of the analyses 
concerned only the first treatments that patients received 
with oncolytic adenoviruses. Viruses were based on either 
Ad5, Ad3 or a modified Ad5/3 capsid, where the Ad5 knob 
had been switched to Ad3 knob [29]. Some of the viruses 
were armed with transgene coding for GM-CSF or CD40 
ligand [28, 62].
Treatments and response evaluation
Imaging response before and after (typically at 3 
months) virus treatments evaluated by computer tomography 
(CT) or positron emission tomography with CT (F18-FDG-
PET-CT). Modified RECIST 1.1 criteria [63] were used for 
assessment of CT results, and previously described PET 
criteria [34] were used for the PET-CT imaging results. 
Responses were graded as progressive disease or progressive 
metabolic disease (PD/PMD), stable disease or stable 
metabolic disease (SD/SMD), minor response or minor 
metabolic response (MR/MMR) and complete response or 
complete metabolic response (CR/CMR).
Serum IL-8 quantification
Serum IL-8 was analyzed from venous blood 
samples after collection using standard laboratory 
techniques. The laboratory reference “normal” value of 
62 ng/l was used as the cutoff to determine high and low 
baseline IL-8 levels. The IL-8 change status was assigned 
based on the changes in IL-8 in samples taken during 
100 days after treatment with oncolytic adenovirus by 
comparing post-treatment values with baseline IL-8 levels. 
A decrease of at least 50% was required for decrease status 
and an increase of at least 100% was required for increase 
status. If no decrease or increase was observed, the patient 
was assigned to the “no change” group.
Tumor load and peripheral blood cell counts
Tumor load was assessed from pre-treatment CT 
and PET-CT images. Based on the metastases in different 
organs and size of the primary tumor a tumor load score 
(0-21) describing the overall tumor load was calculated 
according to previously described methodology [6]. In this 
study tumor load score was available for 60 patients. The 
median of the total tumor load (5) score was determined 
as the cutoff value for high tumor load.
Peripheral blood cell counts were obtained in the 
laboratory of the treating hospital using standard protocols. 
Baseline blood samples were obtained from patients on the 
day of the treatment or one day before. Neutrophil count 
was obtained by subtracting the lymphocyte count from 
total leucocyte count. Neutrophil to lymphocyte ratio was 
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determined by dividing the baseline neutrophil count by 
the lymphocyte count.
RNA microarrays
Gene expression in pre- and post-treatment tumor 
and liquid biopsy samples was analyzed using RNA 
microarrays and following computational methods 
as previously described [24]. Expression data was 
normalized using sample specific normalization to account 
for differential gene expression in different sample 
types. Baseline measurements of serum IL-8 were not 
available for patients with RNA microarray data. The log2 
expression values were compared at baseline to determine 
high and low baseline gene expression. Change in the 
expression value between pre- and post-treatment samples 
was calculated and patients with negative a change were 
grouped into decrease group whereas patients with a 
positive change were assigned to increase group.
Enzyme-linked immunospot (ELISPOT) assay
ELISPOT analysis was carried out using patient 
derived peripheral blood mononuclear cells (PBMCs) as 
described earlier [28]. Stimulation of the PBMCs was 
done using the tumor-associated BIRC5 PONAB peptide 
Survivin (ProImmune) to assess responses for a tumor-
associated antigen. A total of 10 spot forming units were 
regarded as the lower limit of detection for the baseline 
and difference between pre- and post-treatment samples. 
ELISPOT readout changes between -3 and +3 spot 
forming units per well were labeled as “no change”, while 
less than -3 was considered decrease and above 3 increase 
in anti-survivin ELISPOT [25].
Preparation of single-cell suspension from 
primary tumor tissue
Samples were obtained from 6 patients with 
ovarian tumors who had undergone surgical resection 
at the Helsinki University Central Hospital (Helsinki, 
Finland). Patients were surgically treated for expected 
ovarian cancer, but tumor histologies were diverse, and 
some tumors were considered benign in pathologist’s 
assessment (Supplementary Table 4). The local ethics 
committee positively evaluated the collection of samples, 
and the patients gave a written informed consent before 
sample collection. After collection, the samples were 
stored in growth medium on ice for transport. After 
the tumor was surgically removed, necrotic areas were 
removed with scissors and the remaining tumor tissue was 
split into small fragments (~50 mm3 each) using a scalpel. 
For enzymatic digestion, tumor fragments were incubated 
in a sealed, 50 mL Falcon tube with a final volume of 
25 ml enzyme solution containing serum-free RPMI 
1640 supplemented with collagenase type I (170 mg/l), 
collagenase type IV (170 mg/l), DNase I (25 mg/ml) 
and elastase (25 mg/ml) (all enzymes from Worthington 
Biochemical). After overnight digestion at +37 ºC (with 
rocking), which has been shown to not affect the viability 
of the cells [64–66] and was discovered to be necessary for 
producing a quality single-cell suspension, the cells were 
collected, passed through a 100 μm strainer and treated 
with ACK lysis buffer (Life Technologies, Carlsbad, CA) 
to eliminate red blood cells.
Cytotoxicity assay
3.5×105 cells from the single-cell suspension were 
plated on a 96-well plate and treated with Ad5/3-D24 
(10 VP per cell) and/or neutralizing anti-IL-8 antibody 
(2 μg/ml; R&D Systems). Cell viability was determined 
7-13 days later with CellTiter 96 AQueous One Solution 
Proliferation Assay (Promega, Fitchburg, WI).
Immune cell isolation and TIL-TAN co-culture
After single-cell suspension was obtained by 
enzymatic digestion, tumor-infiltrating immune cells 
were isolated using positive selection of CD3+ (TILs) 
or CD15+ (TANs) with magnetic microbeads and 
LS columns according to manufacturer’s instructions 
(Miltenyi Biotec Inc, Bergisch Gladbach, Germany). For 
the co-culture experiment, CD3+ TILs and CD15+ TANs 
were plated at 1:1 ratio (2×105 cells each) in a 96-well 
U-bottom plate containing RPMI 1640 supplemented 
with 10 % FBS, 20 mM L-Glutamine, 1× Pen/Strep 
solution, 15 mM HEPES, 50 μM 2-mercaptoethanol, 1 
mM Na pyruvate and 8×105 beads/ml anti-CD3/anti-CD28 
Dynabeads (Thermo Fisher Scientific, Waltham, MA). In 
addition, recombinant human IL-8 (Peprotech, Rocky 
Hill, NJ) or neutralizing anti-IL-8 antibody was added 
to the co-culture at the final concentration of 500 ng/ml 
and 2 μg/ml, respectively. After 6 days, proliferation of 
CD3+ T cells and activation of CD4+ and CD8+ T cells 
was assessed by flow cytometry. Activation of the CD4+ 
cells was measured at this time point as both oncolytic 
adenoviruses and IL8 are known to affect CD4+ T cells 
[67–69] and 4-6 days of co-culture has been shown to be a 
suitable time window to analyze CD4+ T cell activity and/
or function [70, 71].
Measurement of secreted cytokines
24 hours after plating, supernatant samples 
were collected from the treated TIL-TAN co-cultures 
and stored at -80 ºC until measurement. The levels of 
cytokines and growth factors secreted by the co-cultured 
TILs and TANs were measured using multiplex Flex 
Sets (BD Biosciences, San Jose, CA), Accuri C6 flow 




Statistical analysis was conducted using SPSS 
Statistics v23 (International Business Machines 
Corporation, Armonk, NY), Microsoft Excel (Microsoft 
Corporation, Redmond, WA) and GraphPad Prism 
(GraphPad Software, La Jolla, CA). Differences between 
average IL-8 levels were tested with one-way ANOVA 
and Student’s t-test. Log-rank test was utilized to compare 
overall survival between different IL-8 groups and 
subgroups defined by ELISPOT or NLR measurements. 
Differences in treatment responses between groups were 
analyzed with Fisher’s exact test. Hazard ratios for IL-8 
and patient characteristics were estimated using Cox 
proportional hazards regression model. P smaller than 
0.05 were regarded as statistically significant.
ACKNOWLEDGMENTS AND FUNDING
We thank Susanna Grönberg-Vähä-Koskela for 
expert assistance and Arto Leminen for clinical samples. 
We thank Majlen Fazer and Paul Ehrnrooth for their 
donation. This study was supported by Jane and Aatos 
Erkko Foundation, HUCH Research Funds (EVO), Sigrid 
Juselius Foundation, Biocentrum Helsinki, Biocenter 
Finland, Finnish Cancer Organizations, Finnish Medical 
Foundation, Paulo Foundation, University of Helsinki and 
TILT Biotherapeutics Ltd.
CONFLICTS OF INTEREST
A.H. is employee and shareholder in TILT 
Biotherapeutics Ltd. and shareholder in Targovax ASA.
REFERENCES
1. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer 
N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala 
SS, Milhem M, Cranmer L, Curti B, et al. Talimogene 
laherparepvec improves durable response rate in patients with 
advanced melanoma. J Clin Oncol. 2015; 33:2780–2788.
2. Breitbach CJ, Lichty BD, Bell JC. Oncolytic viruses: 
therapeutics with an identity crisis. EBioMedicine. 2016; 
9:31–36.
3. Simpson GR, Relph K, Harrington K, Melcher A, Pandha 
H. Cancer immunotherapy via combining oncolytic 
virotherapy with chemotherapy: recent advances. Oncolytic 
Virother. 2016; 5:1–13.
4. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat 
Biotechnol. 2012; 30:658–670.
5. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral 
with cancer immunotherapy. Nat Rev Cancer. 2014; 
14:559–567.
6. Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva 
A, Hemminki O, Oksanen M, Gronberg-Vaha-Koskela 
S, Hemminki K, Joensuu T, Hemminki A. Predictive and 
prognostic clinical variables in cancer patients treated with 
adenoviral oncolytic immunotherapy. Mol Ther. 2016; 
24:1323–1332.
7. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a 
new class of immunotherapy drugs. Nat Rev Drug Discov. 
2015; 14:642–662.
8. Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) 
and monocyte chemotactic and activating factor (MCAF/
MCP-1), chemokines essentially involved in inflammatory 
and immune reactions. Cytokine Growth Factor Rev. 1998; 
9:9–23.
9. Xie K. Interleukin-8 and human cancer biology. Cytokine 
Growth Factor Rev. 2001; 12:375–391.
10. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. 
Clin Cancer Res. 2008; 14:6735–6741.
11. Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, 
Martin-Algarra S, Perez G, Landazuri SF, Gonzalez A, 
Gross S, Rodriguez I, Munoz-Calleja C, Rodriguez-Ruiz M, 
Sangro B, et al. Serum interleukin-8 reflects tumor burden 
and treatment response across malignancies of multiple 
tissue origins. Clin Cancer Res. 2014; 20:5697–5707.
12. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez 
C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M. Fully 
human anti-interleukin 8 antibody inhibits tumor growth in 
orthotopic bladder cancer xenografts via down-regulation 
of matrix metalloproteases and nuclear factor-kappab. Clin 
Cancer Res. 2003; 9:3167–3175.
13. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat 
AA, Han LY, Landen CN, Jennings N, De Geest K, Langley 
RR, Villares G, Sanguino A, Lutgendorf SK, et al. Effect 
of interleukin-8 gene silencing with liposome-encapsulated 
small interfering RNA on ovarian cancer cell growth. J Natl 
Cancer Inst. 2008; 100:359–372.
14. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and 
safety of a monoclonal antibody recognizing interleukin-8 
in COPD: a pilot study. Chest. 2004; 126:926–934.
15. Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, 
Satijn D, Knudsen KM, Boot EP, Hudson D, Baadsgaard O, 
Parren PW, van de Winkel JG. IL-8 as antibody therapeutic 
target in inflammatory diseases: reduction of clinical 
activity in palmoplantar pustulosis. J Immunol. 2008; 
181:669–679.
16. Murayama T, Mukaida N, Khabar KS, Matsushima K. 
Potential involvement of IL-8 in the pathogenesis of human 
cytomegalovirus infection. J Leukoc Biol. 1998; 64:62–67.
17. Sato H, Miura R, Kai C. Measles virus infection induces 
interleukin-8 release in human pulmonary epithelial cells. 
Comp Immunol Microbiol Infect Dis. 2005; 28:311–320.
18. Collins PL, Graham BS. Viral and host factors in human 
respiratory syncytial virus pathogenesis. J Virol. 2008; 
82:2040–2055.
19. Booth JL, Coggeshall KM, Gordon BE, Metcalf JP. 
Adenovirus type 7 induces interleukin-8 in a lung slice 
Oncotarget6333www.impactjournals.com/oncotarget
model and requires activation of Erk. J Virol. 2004; 
78:4156–4164.
20. Rajaiya J, Xiao J, Rajala RV, Chodosh J. Human adenovirus 
type 19 infection of corneal cells induces p38 MAPK-
dependent interleukin-8 expression. Virol J. 2008; 5:17.
21. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland 
K, Hau C, Verstegen NJ, Ciampricotti M, Hawinkels LJ, 
Jonkers J, de Visser KE. IL-17-producing gammadelta 
t cells and neutrophils conspire to promote breast cancer 
metastasis. Nature. 2015; 522:345–348.
22. Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella 
E, Gigantino V, Franco R, Marone G, Portella G. The 
oncolytic virus dl922-947 reduces IL-8/CXCL8 and 
MCP-1/CCL2 expression and impairs angiogenesis and 
macrophage infiltration in anaplastic thyroid carcinoma. 
Oncotarget. 2016; 7:1500–1515. https://doi.org/10.18632/
oncotarget.6430.
23. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, 
Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton 
J, Marshall JL, Mace TA, et al. Randomized phase 2 trial 
of the oncolytic virus pelareorep (Reolysin) in upfront 
treatment of metastatic pancreatic adenocarcinoma. Mol 
Ther. 2016; 24:1150–1158.
24. Taipale K, Liikanen I, Juhila J, Turkki R, Tahtinen S, 
Kankainen M, Vassilev L, Ristimaki A, Koski A, Kanerva 
A, Diaconu I, Cerullo V, Vaha-Koskela M, et al. Chronic 
activation of innate immunity correlates with poor prognosis 
in cancer patients treated with oncolytic adenovirus. Mol 
Ther. 2016; 24:175–183.
25. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, 
Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen 
S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, 
et al. Oncolytic adenovirus with temozolomide induces 
autophagy and antitumor immune responses in cancer 
patients. Mol Ther. 2013; 21:1212–1223.
26. Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, 
Oksanen M, Kairemo K, Joensuu T, Kanerva A, Hemminki 
A. Serum HMGB1 is a predictive and prognostic biomarker 
for oncolytic immunotherapy. Oncoimmunology. 2015; 
4:e989771.
27. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe 
C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey 
R, Hodi FS. Guidelines for the evaluation of immune 
therapy activity in solid tumors: immune-related response 
criteria. Clin Cancer Res. 2009; 15:7412–7420.
28. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, 
Ugolini M, Nokisalmi P, Raki M, Laasonen L, Sarkioja 
M, Rajecki M, Kangasniemi L, Guse K, et al. Oncolytic 
adenovirus coding for granulocyte macrophage colony-
stimulating factor induces antitumoral immunity in cancer 
patients. Cancer Res. 2010; 70:4297–4309.
29. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo 
V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, 
Ranki T, Oksanen M, Holm SL, et al. Treatment of cancer 
patients with a serotype 5/3 chimeric oncolytic adenovirus 
expressing GMCSF. Mol Ther. 2010; 18:1874–1884.
30. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, 
Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen 
T, Laasonen L, Partanen K, Kauppinen S, Joensuu T, et al. 
Immunological effects of low-dose cyclophosphamide in 
cancer patients treated with oncolytic adenovirus. Mol Ther. 
2011; 19:1737–1746.
31. Hol J, Wilhelmsen L, Haraldsen G. The murine IL-8 
homologues KC, MIP-2, and LIX are found in endothelial 
cytoplasmic granules but not in weibel-palade bodies. J 
Leukoc Biol. 2010; 87:501–508.
32. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, 
Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, 
Cao Z, Alvarez RD, Curiel DT, et al. Enhanced therapeutic 
efficacy for ovarian cancer with a serotype 3 receptor-
targeted oncolytic adenovirus. Mol Ther. 2003; 8:449–458.
33. Altstaedt J, Kirchner H, Rink L. Cytokine production of 
neutrophils is limited to interleukin-8. Immunology. 1996; 
89:563–568.
34. Koski A, Ahtinen H, Liljenback H, Roivainen A, Koskela 
A, Oksanen M, Partanen K, Laasonen L, Kairemo K, 
Joensuu T, Hemminki A. [(18)F]-fluorodeoxyglucose 
positron emission tomography and computed tomography 
in response evaluation of oncolytic adenovirus treatments 
of patients with advanced cancer. Hum Gene Ther. 2013; 
24:1029–1041.
35. Liikanen I, Monsurro V, Ahtiainen L, Raki M, Hakkarainen 
T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo 
V, Kanerva A, Pesonen S, Marzioni D, et al. Induction of 
interferon pathways mediates in vivo resistance to oncolytic 
adenovirus. Mol Ther. 2011; 19:1858–1866.
36. Ren Y, Poon RT, Tsui H, Chen W, Li Z, Lau C, Yu W, Fan 
S. Interleukin-8 serum levels in patients with hepatocellular 
carcinoma: correlations with clinicopathological features 
and prognosis. Clin Cancer Res. 2003; 9:5996–6001.
37. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck 
E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum 
interleukin-8 in patients with early and metastatic breast 
cancer correlates with early dissemination and survival. 
Clin Cancer Res. 2004; 10:7157–7162.
38. Inozume T, Hanada K, Wang QJ, Yang JC. IL-17 secreted 
by tumor reactive T cells induces IL-8 release by human 
renal cancer cells. J Immunother. 2009; 32:109–117.
39. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, 
O’Sullivan JM, Wilson RH, Johnston PG, Waugh DJ. 
Chemotherapy-induced CXC-chemokine/CXC-chemokine 
receptor signaling in metastatic prostate cancer cells confers 
resistance to oxaliplatin through potentiation of nuclear 
factor-kappab transcription and evasion of apoptosis. J 
Pharmacol Exp Ther. 2008; 327:746–759.
40. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown 
M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, 
Guan J, Dontu G, Wicha MS. CXCR1 blockade selectively 
Oncotarget6334www.impactjournals.com/oncotarget
targets human breast cancer stem cells in vitro and in 
xenografts. J Clin Invest. 2010; 120:485–497.
41. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, 
Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-beta 
inhibition enhances chemotherapy action against triple-
negative breast cancer. J Clin Invest. 2013; 123:1348–1358.
42. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. 
Multiple control of interleukin-8 gene expression. J Leukoc 
Biol. 2002; 72:847–855.
43. Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, 
Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki 
A. An oncolytic adenovirus enhanced for toll-like receptor 
9 stimulation increases antitumor immune responses and 
tumor clearance. Mol Ther. 2012; 20:2076–2086.
44. Kobayashi Y. The role of chemokines in neutrophil biology. 
Front Biosci. 2008; 13:2400–2407.
45. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, 
Worthen GS, Albelda SM. Polarization of tumor-associated 
neutrophil (TAN) phenotype by tgf-beta: “N1” versus “N2” 
tan. Cancer Cell. 2009; 16:183–194.
46. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss 
S. Neutrophils responsive to endogenous IFN-beta regulate 
tumor angiogenesis and growth in a mouse tumor model. J 
Clin Invest. 2010; 120:1151–1164.
47. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen 
TL, Ranganathan A, Deshpande C, Akimova T, Vachani A, 
Litzky L, Hancock WW, Conejo-Garcia JR, Feldman M, 
Albelda SM, et al. Tumor-associated neutrophils stimulate 
T cell responses in early-stage human lung cancer. J Clin 
Invest. 2014; 124:5466–5480.
48. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom 
O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, 
Yang H, Tracey KJ. High mobility group 1 protein (HMG-
1) stimulates proinflammatory cytokine synthesis in human 
monocytes. J Exp Med. 2000; 192:565–570.
49. Dejean E, Foisseau M, Lagarrigue F, Lamant L, Prade N, 
Marfak A, Delsol G, Giuriato S, Gaits-Iacovoni F, Meggetto 
F. ALK+ALCLs induce cutaneous, HMGB-1-dependent 
IL-8/CXCL8 production by keratinocytes through 
NF-kappab activation. Blood. 2012; 119:4698–4707.
50. Chung HW, Jang S, Kim H, Lim J. Combined targeting 
of high-mobility group box-1 and interleukin-8 to control 
micrometastasis potential in gastric cancer. Int J Cancer. 
2015; 137:1598–1609.
51. Vega-Carrascal I, Reeves EP, Niki T, Arikawa T, McNally 
P, O’Neill SJ, Hirashima M, McElvaney NG. Dysregulation 
of tim-3-galectin-9 pathway in the cystic fibrosis airways. J 
Immunol. 2011; 186:2897–2909.
52. Vega-Carrascal I, Bergin DA, McElvaney OJ, McCarthy C, 
Banville N, Pohl K, Hirashima M, Kuchroo VK, Reeves 
EP, McElvaney NG. Galectin-9 signaling through tim-3 is 
involved in neutrophil-mediated gram-negative bacterial 
killing: an effect abrogated within the cystic fibrosis lung. J 
Immunol. 2014; 192:2418–2431.
53. Anderson AC. Tim-3: an emerging target in the cancer 
immunotherapy landscape. Cancer Immunol Res. 2014; 
2:393–398.
54. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski 
KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina 
H, Jones RE, Kulkarni MM, Kuraguchi M, et al. Adaptive 
resistance to therapeutic PD-1 blockade is associated with 
upregulation of alternative immune checkpoints. Nat 
Commun. 2016; 7:10501.
55. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, 
Kim H, Yun CO. Short hairpin RNA-expressing oncolytic 
adenovirus-mediated inhibition of IL-8: effects on 
antiangiogenesis and tumor growth inhibition. Gene Ther. 
2008; 15:635–651.
56. Hemminki A, Oksanen M, Merisalo-Soikkeli M. 
Oncolytic virotherapy trials--letter. Clin Cancer Res. 2013; 
19:4541–4542.
57. Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, 
Joensuu T, Kanerva A, Pesonen S, Alemany R, Hemminki 
A. Verapamil results in increased blood levels of oncolytic 
adenovirus in treatment of patients with advanced cancer. 
Mol Ther. 2012; 20:221–229.
58. Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva 
A, Joensuu T, Kairemo K, Laasonen L, Partanen K, 
Kangasniemi L, Lieber A, Pesonen S, Hemminki A. Ad3-
hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in 
patients with chemotherapy refractory cancer. Mol Ther. 
2012; 20:1821–1830.
59. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, 
Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen 
L, Partanen K, Karli E, Haavisto E, et al. Integrin targeted 
oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-
D24-GMCSF for treatment of patients with advanced 
chemotherapy refractory solid tumors. Int J Cancer. 2012; 
130:1937–1947.
60. Pesonen S, Nokisalmi P, Escutenaire S, Sarkioja M, Raki 
M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka 
C, Guse K, Haavisto E, Oksanen M, Rajecki M, et al. 
Prolonged systemic circulation of chimeric oncolytic 
adenovirus Ad5/3-Cox2L-D24 in patients with metastatic 
and refractory solid tumors. Gene Ther. 2010; 17:892–904.
61. Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, 
Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, 
Cascallo M, Guse K, Rajecki M, Kangasniemi L, et al. 
Oncolytic adenovirus ICOVIR-7 in patients with advanced 
and refractory solid tumors. Clin Cancer Res. 2010; 
16:3035–3043.
62. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva 
A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, 
Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, et al. 
Oncolytic immunotherapy of advanced solid tumors with 
a cd40l-expressing replicating adenovirus: assessment of 
safety and immunologic responses in patients. Cancer Res. 
2012; 72:1621–1631.
Oncotarget6335www.impactjournals.com/oncotarget
63. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, 
Liikanen I, Tahtinen S, Oksanen M, Heiskanen R, Pesonen 
S, Joensuu T, Alanko T, Partanen K, et al. Antiviral and 
antitumor t-cell immunity in patients treated with GM-CSF-
coding oncolytic adenovirus. Clin Cancer Res. 2013; 
19:2734–2744.
64. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang 
H, Reiter RE, Huang J, Witte ON. Purification and direct 
transformation of epithelial progenitor cells from primary 
human prostate. Nat Protoc. 2011; 6:656–667.
65. Boj SF, Hwang C, Baker LA, Chio IIC, Engle DD, Corbo V, 
Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin 
A, Oni T, Yu KH, et al. Organoid models of human and 
mouse ductal pancreatic cancer. Cell. 2015; 160:324–338.
66. Volovitz I, Shapira N, Ezer H, Gafni A, Lustgarten M, Alter 
T, Ben-Horin I, Barzilai O, Shahar T, Kanner A, Fried I, 
Veshchev I, Grossman R, et al. A non-aggressive, highly 
efficient, enzymatic method for dissociation of human 
brain-tumors and brain-tissues to viable single-cells. BMC 
Neurosci. 2016; 17:30.
67. Taipale K, Liikanen I, Juhila J, Karioja-Kallio A, Oksanen 
M, Turkki R, Linder N, Lundin J, Ristimaki A, Kanerva A, 
Koski A, Joensuu T, Vaha-Koskela M, et al. T cell subsets 
in peripheral blood and tumors of patients treated with 
oncolytic adenoviruses. Mol Ther. 2015; 23:964–973.
68. Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, M 
Nettlebeck D, Han Y, Zhang L, Lesniak MS. Intratumoral 
oncolytic adenoviral treatment modulates the glioma 
microenvironment and facilitates systemic tumor-antigen-
specific t cell therapy. Oncoimmunology. 2015; 4:e1022302.
69. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, 
Nakayama E. Enrichment of Foxp3+ CD4 regulatory t cells 
in migrated t cells to IL-6- and IL-8-expressing tumors 
through predominant induction of cxcr1 by il-6. J Immunol. 
2010; 185:6734–6740.
70. Charron L, Doctrinal A, Ni Choileain S, Astier AL. 
Monocyte:T-cell interaction regulates human T-cell 
activation through a CD28/CD46 crosstalk. Immunol Cell 
Biol. 2015; 93:796–803.
71. Pattarini L, Trichot C, Bogiatzi S, Grandclaudon M, 
Meller S, Keuylian Z, Durand M, Volpe E, Madonna S, 
Cavani A, Chiricozzi A, Romanelli M, Hori T, et al. Tslp-
activated dendritic cells induce human t follicular helper 
cell differentiation through OX40-ligand. J Exp Med. 2017; 
214:1529–1546.
